# GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

> **NCT00381303** · PHASE3 · COMPLETED · sponsor: **Tibotec, Inc** · enrollment: 429 (actual)

## Conditions studied

- HIV
- Infectious

## Interventions

- **DRUG:** darunavir
- **DRUG:** ritonavir

## Key facts

- **NCT ID:** NCT00381303
- **Lead sponsor:** Tibotec, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-12
- **Target enrollment:** 429 (ACTUAL)
- **Last updated:** 2014-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381303, "GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00381303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*